Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

814.86 -8.95 (-1.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 560,250
Open 824.94
Bid (Size) 814.50 (1)
Ask (Size) 824.20 (1)
Prev. Close 823.81
Today's Range 808.89 - 828.42
52wk Range 668.00 - 853.97
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga

Performance

YTD
+13.10%
+13.10%
1 Month
-0.48%
-0.48%
3 Month
-0.98%
-0.98%
6 Month
+8.61%
+8.61%
1 Year
+6.32%
+6.32%

More News

Read More
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
11 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Soaring Stocks to Buy and Hold
Via The Motley Fool
Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers
Via Investor's Business Daily
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Via InvestorPlace
Topics Economy
Exposures Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
Via InvestorPlace
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
Via Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Via Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Via Investor's Business Daily
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
Via Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
Via Benzinga
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.